Bavarian Nordic A/S (0DPB.L)
| Previous close | 305.93 |
| Open | 323.40 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 318.40 - 326.90 |
| 52-week range | 171.45 - 410.70 |
| Volume | |
| Avg. volume | 44,021 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 21 Aug 2024 - 26 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireBavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizations COPENHAGEN, Denmark, July 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a type II variation for IMVANEX® (MVA-BN) smallpox and mpox vaccine, including real-world effectiveness dat
GlobeNewswireBavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
EMA will now initiate its centralized review procedure under accelerated assessment for Bavarian Nordic’s chikungunya vaccine COPENHAGEN, Denmark, July 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA), which was submitted in June 2024 for CHIKV VLP, the Company’s vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age an
- Globe Newswire
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
COPENHAGEN, Denmark, July 1, 2024 – Bavarian Nordic today announced the conversion of its existing undrawn DKK 1 billion syndicated revolving credit facility (RCF) into a sustainability-linked loan (SLL). The RCF agreement, entered with Danske Bank and Nordea in October 2023, has a three-year tenor with two one-year extension options and provides additional financial flexibility, e.g., to absorb fluctuations in working capital or to fulfil periodic significant milestone payments related to previ
